Mankind Pharma
Mankind Pharma, a prominent player in the Indian pharmaceutical industry, is headquartered in New Delhi, India. Founded in 1991, the company has established itself as a leader in the development, manufacturing, and marketing of a diverse range of pharmaceutical products, including prescription medications, over-the-counter drugs, and consumer healthcare items. With a strong focus on quality and innovation, Mankind Pharma has achieved significant milestones, including rapid expansion across major operational regions in India and beyond. The company is renowned for its unique formulations and commitment to affordable healthcare, positioning itself as a trusted name among healthcare professionals and consumers alike. Notable achievements include a robust market presence and recognition for its contributions to the pharmaceutical sector, making Mankind Pharma a key player in enhancing health outcomes across the region.
DitchCarbon Score
How does Mankind Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Mankind Pharma's score of 35 is higher than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Mankind Pharma's reported carbon emissions
In 2024, Mankind Pharma reported total carbon emissions of approximately 5,831,000 kg CO2e for Scope 1 and about 17,335,000 kg CO2e for Scope 2. This marks a significant increase from 2023, where emissions were approximately 14,519,000 kg CO2e for Scope 1 and about 29,077,000 kg CO2e for Scope 2. The company has not disclosed any Scope 3 emissions data for 2024, but in 2022, it reported approximately 168,000 kg CO2e in this category. Mankind Pharma's emissions intensity per rupee of turnover for Scope 1 and Scope 2 in 2024 was about 0.004805 INR, reflecting a commitment to improving efficiency. The company has not set specific reduction targets or climate pledges, nor does it participate in initiatives such as the Science Based Targets initiative (SBTi) or the Carbon Disclosure Project (CDP) for emissions reduction. Overall, while Mankind Pharma has made strides in tracking its emissions, the absence of reduction targets indicates a need for further commitment to climate action.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 15,753,000 | 00,000,000 | 0,000,000 |
| Scope 2 | 28,074,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 168,000 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Mankind Pharma is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
